WAM
JBIO

Warberg Asset Management’s Jade Biosciences JBIO Stock Holding History

Warberg Asset Management’s Portfolio JBIO Stock Details JBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1,927
Closed -$111K – 213
2024
Q2 		$111K Buy
+1,927
New +$1.28M 0.02% 131

Other funds holding JBIO

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

Warberg Asset Management's JBIO Position: Q3 2024 in Review

Warberg Asset Management sold out of Jade Biosciences (JBIO) in Q3 2024, closing a stake of 1,927 shares — an estimated $111K sold.

Warberg Asset Management first reported a position in JBIO in Q2 2024 and held it in 1 quarter. The position peaked at $111K in Q2 2024. 72 funds tracked by Wall St. Rank hold JBIO as of Q3 2024.

  • Warberg Asset Management reported no remaining Jade Biosciences position as of Q3 2024 after selling out during the quarter.
  • Warberg Asset Management sold 1,927 Jade Biosciences shares in Q3 2024, an estimated $111K.
  • Warberg Asset Management first reported a position in Jade Biosciences in Q2 2024 and held it in 1 quarter.
  • Warberg Asset Management's Jade Biosciences position peaked at $111K in Q2 2024.
  • 72 funds tracked by Wall St. Rank held Jade Biosciences as of Q3 2024.

Based on Warberg Asset Management's 13F filing for Q3 2024, filed 6 Nov 2024.